Sofia Georgia Pantazi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sofia Georgia Pantazi has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Andreas Ch Lazaris
First Department of Pathology, School of Medicine, The National and Kapodistrian University of Athens, 11527 Athens, Greece
1 shared publication - Athanasia Varvaresou
Sector of Aesthetics and Cosmetic Science, Department of Biomedical Sciences, School of Health and Care Sciences, University of West Attica, 28 Ag. Spyridonos Str., Panepistimioupolis Egaleo Park, 12243 Athens, Greece
1 shared publication - Dimitrios Chaniotis
Department of Biomedical Sciences, University of West Attica, Agioy Spyridonos 28, 12243 Egaleo, Greece
1 shared publication - Effie G. Papageorgiou
Laboratory of Reliability and Quality Control in Laboratory Hematology (HemQcR), Department of Biomedical Sciences, School of Health & Caring Sciences, University of West Attica (UniWA), 12243 Egaleo, Greece
1 shared publication - Evaggelia Protopapa
Department of Biomedical Sciences, School of Health and Care Sciences, University of West Attica, 12243 Athens, Greece
1 shared publication - Foteini Biskanaki
First Department of Pathology, School of Medicine, The National and Kapodistrian University of Athens, 11527 Athens, Greece
1 shared publication
Latest Publications
- Open Access
Longitudinal Changes in Systemic Total Oxidant Status Following High-Intensity Focused Ultrasound for Facial Rejuvenation: A Prospective 6-Month Controlled Pilot Study
High-intensity focused ultrasound (HIFU) is widely used for non-invasive facial and neck rejuvenation; however, its longer-term systemic biochemical effects remain insufficiently characterized. This prospective controlled pilot study investigated longitudinal changes in systemic oxidative status at baseline and 3 and 6 months following a single HIFU treatment. Thirty healthy adults were enrolled, including 25 participants who underwent facial and neck HIFU and 5 untreated participants serving as a comparison group. Serum total oxidant status (TOS) was quantified using an enzyme-linked immunosorbent assay (ELISA)-based method, and longitudinal changes were assessed using mixed-effects modeling. Baseline TOS did not differ significantly between groups (19.54 ± 1.49 vs. 19.78 ± 1.81 μmol/L; p = 0.794). A significant group × time interaction was observed (Wald χ2(2) = 21.78, p < 0.001). Within the HIFU group, TOS decreased at 3 months (17.31 ± 1.51 μmol/L; Bonferroni-adjusted p < 0.001) and remained below baseline at 6 months (18.34 ± 0.95 μmol/L; p < 0.001), despite a partial increase between 3 and 6 months (p = 0.002). Three participants (12.0%) reported mild, transient deep-tissue tenderness; no serious adverse events occurred. Overall, HIFU was associated with a distinct longitudinal TOS pattern, supporting further investigation of redox and tissue-remodeling biomarkers.
Open AccessLongitudinal Changes in Systemic Total Oxidant Status Following High-Intensity Focused Ultrasound for Facial Rejuvenation: A Prospective 6-Month Controlled Pilot Study
High-intensity focused ultrasound (HIFU) is widely used for non-invasive facial and neck rejuvenation; however, its longer-term systemic biochemical effects remain insufficiently characterized. This prospective controlled pilot study investigated longitudinal changes in systemic oxidative status at baseline and 3 and 6 months following a single HIFU treatment. Thirty healthy adults were enrolled, including 25 participants who underwent facial and neck HIFU and 5 untreated participants serving as a comparison group. Serum total oxidant status (TOS) was quantified using an enzyme-linked immunosorbent assay (ELISA)-based method, and longitudinal changes were assessed using mixed-effects modeling. Baseline TOS did not differ significantly between groups (19.54 ± 1.49 vs. 19.78 ± 1.81 μmol/L; p = 0.794). A significant group × time interaction was observed (Wald χ2(2) = 21.78, p < 0.001). Within the HIFU group, TOS decreased at 3 months (17.31 ± 1.51 μmol/L; Bonferroni-adjusted p < 0.001) and remained below baseline at 6 months (18.34 ± 0.95 μmol/L; p < 0.001), despite a partial increase between 3 and 6 months (p = 0.002). Three participants (12.0%) reported mild, transient deep-tissue tenderness; no serious adverse events occurred. Overall, HIFU was associated with a distinct longitudinal TOS pattern, supporting further investigation of redox and tissue-remodeling biomarkers.